Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fixed-Dose Combination · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Fixed-Dose Combination (FDC) Tablet | DRUG | Obicetrapib/Ezetimibe FDC tablet |
The Fixed-Dose Combination is an investigational small molecule tablet being developed by NewAmsterdam Pharma Company N.V. (ticker NAMS). It combines obicetrapib and ezetimibe in a single oral dose. The program is in Phase 1 clinical development, and the specific patient population it is intended to treat has not been disclosed.
The Fixed-Dose Combination is being studied as a single-tablet combination of obicetrapib and ezetimibe. Its intended therapeutic indication has not been publicly disclosed. The only completed clinical study to date was conducted in healthy volunteers and examined how food affects the absorption of the combination, not a disease endpoint.
NewAmsterdam Pharma Company N.V., which trades under the ticker NAMS, is the developer of the Fixed-Dose Combination tablet. The company is running the clinical development program for this obicetrapib and ezetimibe combination product.
The Fixed-Dose Combination is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active. That completed study enrolled 28 participants.
One clinical trial has evaluated the Fixed-Dose Combination: NCT06050291, titled Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe. The Phase 1 study enrolled 28 healthy volunteers, was uncontrolled, and has been completed. It assessed food effects on bioavailability rather than efficacy.